BOSTON, Oct. 17 /PRNewswire/ -- Surface Logix Inc. announced that Jim
Mahoney, President and Chief Executive Officer, will present an update of
the company's drug development pipeline at the 2006 BIO Investor Forum on
October 19, 2006 at 10:20 a.m. Pacific (1:20 p.m. Eastern) Time from The
Palace Hotel in San Francisco.
Surface Logix Inc. currently has two programs in human clinical trials
with a third program approaching its initial regulatory submission. Mr.
Mahoney will discuss the latest results for SLx-2101, currently in Phase
IIa, a second generation PDE5 inhibitor designed to address cardiovascular
indications including Raynaud's Syndrome and Hypertension; and SLx-4090,
soon to be in Phase IIa, a first in class enterocyte specific MTP inhibitor
targeting unmet needs in dyslipidemia and metabolic disorders.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to
create new small molecule drugs that are optimized to meet the challenges
of human physiology. The company is advancing multiple internal programs
focused primarily on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit http://www.surfacelogix.com.
Contact:
David H. Donabedian, Ph.D.
Vice President, Business Development
617.746.8520
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
SOURCE Surface Logix Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
David H. Donabedian, Ph.D., Vice President,
Business Development for Surface Logix Inc., +1-617-746-8520, or
Kari Watson of MacDougall Biomedical Communications Inc. for
Surface Logix Inc., +1-508-647-0209, kwatson@macbiocom.com
|
